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Abstract
Background and Rationale: Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity.
The adverse events are preceded by acute worsening of oral glucose tolerance (oGTT) along with reduced plasma free fatty
acids (FFA) and leptin in animal models. It is unclear whether the same acute effects occur in humans.
Methodology/Principal Findings: A double blind, randomized, placebo-controlled crossover trial was conducted to
examine the potential metabolic effects of olanzapine in healthy volunteers. Participants included male (8) and female (7)
subjects [18–30 years old, BMI 18.5–25]. Subjects received placebo or olanzapine (10 mg/day) for three days prior to oGTT
testing. Primary endpoints included measurement of plasma leptin, oral glucose tolerance, and plasma free fatty acids (FFA).
Secondary metabolic endpoints included: triglycerides, total cholesterol, high- and low-density lipoprotein cholesterol, heart
rate, blood pressure, body weight and BMI. Olanzapine increased glucose Area Under the Curve (AUC) by 42% (28086474
vs. 39846444 mg/dl?min; P=0.0105) during an oGTT. Fasting plasma leptin and triglycerides were elevated 24% (Leptin:
6.861.3 vs. 8.461.7 ng/ml; P=0.0203) and 22% (Triglycerides: 88.9610.1 vs. 108.2611.6 mg/dl; P=0.0170), whereas FFA
and HDL declined by 32% (FFA: 0.3860.06 vs. 0.2660.04 mM; P=0.0166) and 11% (54.264.7 vs. 48.964.3 mg/dl;
P=0.0184), respectively after olanzapine. Other measures were unchanged.
Conclusions/Significance: Olanzapine exerts some but not all of the early endocrine/metabolic changes observed in rodent
models of the metabolic side effects, and this suggest that antipsychotic effects are not limited to perturbations in glucose
metabolism alone. Future prospective clinical studies should focus on identifying which reliable metabolic alterations might
be useful as potential screening tools in assessing patient susceptibility to weight gain and diabetes caused by atypical
antipsychotics.
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Introduction
The advent of atypical antipsychotics represented a significant
improvement in the treatment of schizophrenia and other
psychoses, with these newer drugs lacking most of the debilitating
movement side effects of first generation compounds. Over the last
decade it has become clear that these second generation drugs
possessed other significant adverse effects with chronic treatment.
The adverse effects are in the endocrine-metabolic and body
weight categories. They include body weight gain, increased
adiposity, insulin resistance, diabetes, and dyslipidemia [1], [2],
[3], [4], [5], [6], [7], [8]. The close association of these metabolic
sequelae with atypical antipsychotics, a popular and multi-billion
dollar per year drug class, has led to efforts to further characterize
the adverse events in order to discover new ways to screen or
prevent the resulting obesity and diabetes, which have already
reached epidemic proportions in the general population [9], [10],
[11].
Understanding the mechanism of these side effects has been
challenging. Most clinical studies seeking to elucidate these
mechanisms have been conducted in patient samples after months
to years of chronic treatment with antipsychotics. Mechanistic
insights into the cause of the obesity and diabetes in such studies
have to take into account the multiple potential sources of the
effects including the direct actions of the drugs as well as the
differential drug effects on weight gain, food intake, physical
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mental illness, e.g. [12], which may have genetic and/or lifestyle
factors [13], [14], [15]. In longer-term studies, it is more difficult to
ascertain which effects are secondary to obesity and diabetes and
which are primarily caused by the atypical antipsychotics. For
example one finding from chronic studies has been that olanzapine
decreases FFA despite its ability to also cause diabetes or insulin
resistance [16], [17]. This is paradoxical because diabetes and
insulin resistance are normally associated with elevated FFA not
lower FFA. Despite these challenges, a considerable amount of
basic and clinical research has focused on unraveling the mole-
cular mechanisms of these adverse effects. Since the most severe
diabetes and obesity in patients are observed with olanzapine and
clozapine therapy, reviewed in refs: [18], [19], these two com-
pounds have, understandably, become the focus of much of the
work in animal models.
Some of the chronic metabolic effects of these drugs, such as
increased plasma glucose and decreased FFA, occur rapidly in
animal models and thus imply that they could precede as opposed
to follow the development of obesity. For example, several atypical
antipsychotics, including olanzapine, have been shown to exhibit
rather early and sustained metabolic and endocrine effects
beginning within minutes to hours following drug administration
[20], [21], [22], [23]. This time course could be important because
if these effects occur early before confounding factors set in, it
would improve the chances of understanding the underlying
mechanism. A caveat is that recent data from animal studies have
raised a number of questions about the relevance of animal models
to the clinical problem. For example, in contrast to humans, drug-
induced hyperphagia in response to olanzapine is sexually
dimorphic in rat models, with female rats exhibiting robust
increases in food intake and body weight gain in contrast to males
which do not show this robust effect [24], [25], [26], [27]. In fact,
clozapine fails to cause hyperphagia in either female or male
rodents. Nevertheless, both drugs increase visceral adiposity,
impair glucose tolerance, and decrease lean muscle mass in rodent
models [20], [23], [28].
Clinical studies validating these acute effects are lacking,
especially because of the challenge of isolating these effects in
a schizophrenic population. However, such information would
help us understand if animal models accurately reflect human
physiology in this regard. If so, this would provide a reasonable
rationale to support subsequent studies to determine the mecha-
nisms of these effects and their relevance to the development of
obesity and diabetes. This would effectively allow researchers to
better define the acute metabolic effects in human subjects in
hopes of validating animal studies, while at the same time
focusing the direction of future laboratory efforts on biology that
translates to the bedside. Therefore, we decided to examine
whether some of the acute metabolic changes that have been
observed in rodents treated with atypical antipsychotics also
occurred in humans.
In the following report we demonstrate that acute (3 day)
olanzapine administration in healthy volunteers is associated with
changes in metabolic parameters, including impaired glucose
tolerance, increased triglycerides, and decreased high-density
lipoprotein cholesterol without changes in low-density lipoprotein
or total cholesterol levels. Evidence suggests that drug-induced
changes in plasma leptin concentration, whose potential decrease
had been hypothesized to trigger hyperphagia in rats, may not be
clinically relevant. Finally, olanzapine was associated with
decreased circulating free fatty acids, a finding described in recent
clinical and animal studies, which may give fresh insight to the
mechanism of these metabolic side effects.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The institutional review board of Penn State University College
of Medicine approved the study, including the protocol, scientific
rationale, subject safety, recruitment fliers and other study
advertisements. The study, A Double-blind, Placebo-controlled, Crossover
Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose
Tolerance and Free Fatty Acids in Healthy Volunteers, was registered
online as part of the National Institutes of Health clinical trials
database (Clinicaltrials.gov registration number NCT00741026).
Participants
All healthy subjects were recruited by IRB-approved fliers and
screened for eligibility prior to enrollment in the study. Volun-
teers 18 to 30 years of age with body mass indices of 18.5 to
25 kilograms per square meter with the ability to swallow tablets
and give informed consent were eligible for the study. Subjects
who met any of the following criteria were excluded: (1) Any
DSM-IV TR Axis I psychiatric disorder (except nicotine depen-
dence); (2) Presence of a medical disorder that may confound the
assessment of relevant biologic measures, including: significant
organ system dysfunction, metabolic diseases, type 1 diabetes
mellitus, type 2 diabetes mellitus, pregnancy, endocrine disease,
coagulopathy, clinically significant anemia, or acute infection; (3)
Subjects who have taken any antipsychotic medication within the
last 6 months; (4) Personal or family history of seizures or cardiac
arrhythmias. A total of 42 individuals were screened between July
2008 and June 2009, and of those individuals 15 subjects were
eligible based on inclusion/exclusion criteria.
Study Design and Interventions
The study was conducted at the General Clinical Research
Center (GCRC) of the Milton S. Hershey Medical Center / Penn
State Hershey College of Medicine. There were no major changes
to the study protocol after initiation of the study. Given the
considerable variation in human research subjects, we opted for a
crossover design in which each subject would serve as his/her own
control to improve sensitivity for detection of acute hormonal
and/or metabolic changes. Treatment sequence assignment was
determined using blocked randomization (block size=4) to ensure
balance across the study recruitment period. The SAS statistical
software system version 9.1 (SAS Inc. Cary, NC) was used to
program the randomization algorithm. The Investigational Drug
Service at the Milton S. Hershey Medical Center prepared blinded
olanzapine (Eli Lilly, USA) and placebo tablets according to the
randomization algorithm. The subjects participating in the study,
the study investigators, and the nursing staff in the GCRC were
blind to the intervention type until the conclusion of the study.
The only exception to this was one episode requiring un-blinding
of a subject who developed orthostatic hypotension 24 h after
completing the study.
Written informed consent was obtained from all qualifying
subjects prior to the beginning of the study. The staff in the GCRC
at Penn State handled all subject recruitment. Subjects were
randomized to receive three days of oral olanzapine (10 mg/day)
or placebo in a double-blind fashion. This dose of olanzapine was
used because it is within the range of commonly used starting
doses in patients receiving olanzapine for psychotic symptoms and
is comparable to previous studies in healthy volunteers [16], [29],
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three consecutive evenings. On the morning following the final
dose of olanzapine or placebo, the subjects reported to the GCRC
after an overnight fast for blood collection and an oral glucose
tolerance test. Volunteers had a minimum of two weeks for ‘wash-
out’ between crossovers and returned within four weeks of com-
pleting the first arm of the trial for their second visit to complete
the study. Thus, subjects completed both arms of the trial within
approximately four weeks.
The primary study endpoint of the study was leptin concentra-
tion, placebo compared to olanzapine treatment, which was based
on previous rodent studies [25], [31]. Secondary metabolic end-
points included: oral glucose tolerance, free fatty acids, triglycer-
ides, total cholesterol, and high- and low-density lipoprotein
cholesterol, heart rate, blood pressure, body weight and BMI.
Study Follow-Up and Adverse Events
Participants in the trial were followed-up via telephone call
approximately 4–6 weeks after completion of the study and
screened for additional side effects or changes in their health that
they had experienced since their participation. There were no
unanticipated adverse events during the study; however, there
were several anticipated side effects observed in the olanzapine
arm likely related to active drug treatment. These anticipated
effects included the one episode of orthostatic hypotension that
required un-blinding, as well as six episodes of volunteers
subjectively reporting feeling ‘‘tired’’, ‘‘fatigued’’ or ‘‘worn-down’’.
Individuals also reported having ‘‘dry mouth’’ during the study
arm that corresponded to active drug treatment.
Oral Glucose Tolerance Test
Subjects were given explicit instructions and patient handout
information on how to consume a high carbohydrate diet throug-
hout the 3-day duration for each of the study arms. Subjects
refrained from exercising (i.e. aerobic or anaerobic) during each of
the three-day periods prior to the glucose tolerance testing. All oral
glucose tolerance testing was conducted in the morning. These
tests were conducted at the same time of the morning to minimize
variability because of known circadian influences on glucose
homeostasis and insulin secretion [32], [33]. After an overnight
fast of approximately 10–12 h, baseline blood samples were
collected. Subsequently, subjects drank a bolus solution containing
75 g of glucose (Fisher Health care: FisherBrand 75 SUN-DEX,
cat # 401223FB), at which the time was recorded as zero (t=0).
Serial blood samples were then collected every 30 minutes for two
hours (t=30, 60, 90, 120). Blood samples were immediately
centrifuged at 1,8006 g for 10 minutes and plasma and serum
frozen for future analysis.
Metabolite and Hormone Assays
Plasma glucose concentrations were measured using glucose
oxidase membranes (Yellow Springs Instrument Company, Yellow
Springs, Ohio). Plasma insulin and leptin concentrations were
measured using commercially available double-antibody radioim-
munoassays (Millipore, Billerica, MA). Blood lipid panels (i.e. total
cholesterol, low-density lipoprotein cholesterol, high-density lipo-
protein cholesterol, triglycerides) and free fatty acid concentrations
were determined enzymatically and spectrophotometrically (Quest
Diagnostic Labs; Camp Hill, Pennsylvania). To limit inter-assay
variability, samples from each subject’s placebo and active
treatment arms were assayed together after completion of the
study. Leptin assays were completed in total at the conclusion of
the study.
Statistical Methods
For all results, data are summarized numerically with mean and
standard deviation and displayed with standard box plots. The
study was primarily powered (90% Power) to detect a difference in
serum leptin concentration between the placebo and olanzapine
arms of the crossover study. Power and sample size calculations
were based on previous studies [25], [31] using the method of
Senn [34], and calculated using a conservative estimate of within-
subject correlation and assuming a modest correlation benefit for
the crossover design. Wilcoxon signed-rank tests were used to
calculate significant differences (P,0.05) compared to placebo
treatment. All statistical analyses were completed with GraphPad
Prism and/or InStat computer software (GraphPad Software, San
Diego, CA).
Results
Subject Characteristics and Anthropometric Data
We conducted a double blind, randomized, placebo-controlled
trial to detect acute metabolic effects of olanzapine in healthy
volunteers. The CONSORT 2010 flow diagram of this study is
shown in Fig. 1. Of the individuals screened, fifteen individuals (8
males and 7 females) began the trial, though one individual
dropped out of the study during the final visit to complete the
study. This was due to emesis which the volunteer experienced
after beginning the oral glucose tolerance test, which took place
after all other laboratory samples for analysis had been collected.
Thus, data from this participant is included for all study endpoints
except glucose tolerance testing. The remaining fourteen individ-
uals that began the trial completed both study arms in a double
blind, crossover, and randomized fashion according to the
approved study protocol.
The study was designed to enroll a total of sixteen healthy
volunteers and for each volunteer to complete both study arms (i.e.
placebo and olanzapine) prior to stopping the study, un-blinding,
and beginning data analysis. However, the study was stopped
prematurely secondary to lack of funding after only recruiting
fifteen eligible study subjects. Nevertheless, after officially stopping
the study it was decided to un-blind the data collected to date from
the participants that had completed the study for analysis.
The average age of the subjects was 26.660.5 years. When
analyzing sexes separately, the mean ages of male and female
subjects did not differ significantly (27.060.6 vs. 26.261.0 years,
respectively). Neither bodyweight nor BMI differed significantly in
either treatment arm when placebo and olanzapine arms of the
study were compared overall or with respect to sex (Table 1).
Other baseline characteristics that were measured included heart
rate and systolic and diastolic blood pressures, none of which
differed between treatment arms when analyzed together or with
respect to sex.
Effects of Olanzapine on Leptin and Glucose Tolerance
Leptin concentrations increase with antipsychotic-induced
weight gain as expected with increased adiposity [35], [36],
though we demonstrated that olanzapine decreased circulating
leptin in rats prior to the onset of hyperphagia and adiposity,
suggesting that it may have triggered this response [20], [25]. It is
not clear whether this occurs clinically, but it is feasible that a
disproportionately low leptin for a given degree of adiposity could
drive increased food intake by patients [37]. However, in the
current study median fasting leptin (Fig. 2) was not decreased, but
rather increased by 24% following olanzapine treatment (6.861.3
vs. 8.461.7 ng/ml; P=0.0203), suggesting that attenuated leptin is
not involved in drug-induced hyperphagia.
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though the rapidity of changes to glucose tolerance and/or insulin
sensitivity in patients is unknown. Animal models [20], [22], [25],
[38], [39] have demonstrated that changes in glucose tolerance
and insulin sensitivity are detectable within hours to days following
drug administration, prior to the onset of hyperphagia or
detectable weight gain. Oral glucose tolerance testing following
three days of olanzapine or placebo treatment in healthy
Figure 1. CONSORT 2010 Flow Diagram. The schema graphically outlines the design and conduct of the clinical study.
doi:10.1371/journal.pone.0022662.g001
Table 1. Subject characteristics following placebo and olanzapine treatment.
Sex Condition Weight (kg) BMI (kg/m
2) Heart Rate (bpm) Systolic BP (mmHg) Diastolic BP (mmHg)
Total Placebo 68.262.9 23.060.5 69.962.6 113.362.8 68.362.0
(n=15) Olanzapine 68.963.0 23.060.6 67.663.5 111.763.1 69.561.8
Male Placebo 76.562.6 23.160.7 67.964.2 118.564.0 72.060.8
(n=8) Olanzapine 77.762.6 23.360.8 63.064.5 115.365.1 71.462.7
Female Placebo 58.762.0 22.860.8 72.363.1 107.362.7 64.063.6
(n=7) Olanzapine 58.862.0 22.660.8 72.965.2 107.662.9 67.462.3
Results are expressed as the mean 6 S.E.
doi:10.1371/journal.pone.0022662.t001
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(AUC) for glucose was increased by 42% following olanzapine
treatment (28086474 vs. 39846444 mg/dl?min; P=0.0105). The
AUC insulin (Fig. 3B) did not differ between the placebo and
olanzapine treatment (43906664 vs. 45076579 mU/ml?min), though
there was a trend for higher plasma insulin values in the olanzapine
group (12.761.0 vs. 14.561.1 mU/ml, n=15).
Effects of Olanzapine on Blood Lipids and Cholesterol
In addition to insulin resistance and body weight gain, olanza-
pine and other antipsychotics are associated with dyslipidemia, a
known risk factor for coronary artery disease [40]. To characterize
the potential effects of olanzapine on other metabolites associated
with insulin resistance and the metabolic syndrome, circulating
concentrations of free fatty acids, triglycerides, and cholesterol (i.e.
Total, HDL, LDL) were measured following each treatment arm.
Insulin resistant states, like obesity and diabetes, are typically
associated with higher rather than lower concentrations of FFAs,
secondary to decreased insulin-mediated suppression of lipolysis
from adipose stores. As mentioned earlier chronic olanzapine has
been paradoxically reported to decrease FFA. Consistent with the
findings in chronic studies, median free fatty acid concentration
(Fig. 4) was ,36% lower following acute olanzapine treatment
(0.3860.06 vs. 0.2660.04 mM; P=0.0166).
Given the prevalence of cardiovascular risk factors known
to occur in schizophrenic patients [41], [42], we measured
cholesterol and triglyceride concentrations in our healthy subjects
to determine any baseline effects of olanzapine (Figs. 5 and 6).
Neither total cholesterol (156.869.1 vs. 152.6610.1 mg/dl), nor
did the low-density lipoprotein fraction differ between placebo and
olanzapine treatment (82.766.6 vs. 81.767.8 mg/dl). However,
median high-density lipoprotein cholesterol was modestly de-
creased by 10% in the olanzapine group (54.264.7 vs. 48.96
4.3 mg/dl; P=0.0184). Furthermore, the median triglyceride
concentration was increased by 22% (88.9610.1 vs. 108.2611.6
mg/dl; P=0.0170) after olanzapine treatment. Together these
changes translated into a ,14% increase in the TG:HDL ratio, a
sensitive marker of insulin resistance (P=0.010). Thus, acute
olanzapine administration appears to be associated with negative
changes in blood lipid profiles even in otherwise healthy subjects.
Discussion
In this study we have shown that olanzapine treatment is
associated with metabolic effects that are detectable as early as the
third treatment day, effects that may be involved in the obesigenic
and diabetogenic propensities of olanzapine and other atypical
antipsychotics. These metabolic effects included an elevated AUC
glucose during oral glucose tolerance testing, consistent with
alterations in whole-body insulin sensitivity and/or pancreatic
beta-cell secretion of insulin. Secondly, olanzapine was associated
with increased concentrations of leptin and triglycerides, factors
consistently elevated in obesity and diabetes. Paradoxically, free
fatty acids concentrations, which are typically elevated in insulin
resistant states, were actually found to be lower following olanza-
pine treatment. Finally, there was a small but significant decrease
in high-density lipoprotein cholesterol in the olanzapine study
arm, in the absence of changes in total and low-density lipoprotein
Figure 2. Effect of olanzapine on plasma leptin. Baseline fasting
blood samples were drawn approximately 10–12 h following the final
dose of olanzapine or placebo tablets. Plasma leptin was measured at
the conclusion of the study for each subject under placebo- and
olanzapine-treated conditions. Data are expressed as a box plot for
placebo and olanzapine-treated subjects. An asterisk indicates (P=0.02)
a significant difference between the medians of the placebo and
olanzapine groups using a Wilcoxon matched-pairs signed rank test
(n=15).
doi:10.1371/journal.pone.0022662.g002
Figure 3. Effects of olanzapine on the glucose and insulin
responses during oral glucose challenge. Blinded olanzapine or
placebo tablets were self-administered by healthy volunteers for three
days prior to conduction of a standard oral glucose tolerance test. In the
morning, approximately 10–12 h following the final dose of placebo or
drug compound, baseline blood samples were collected and then
volunteers self-administered an oral glucose-containing solution. Serial
blood samples were drawn at 30 min intervals for two hours. Plasma
glucose and insulin concentrations were determined for each time
point of the tolerance test. Area under the curve for (A) Glucose and (B)
Insulin were calculated for each individual oral glucose tolerance test
under placebo and active drug conditions. Data are expressed as box
plots for the placebo and olanzapine-treated subjects. An asterisk
indicates (P=0.011) a significant difference between the medians of the
placebo and olanzapine groups using a Wilcoxon matched-pairs signed
rank test (n=14).
doi:10.1371/journal.pone.0022662.g003
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such rapid metabolic effects of any of the atypical antipsychotics in
humans. Importantly, the results of this study are comparable to
and extend previous observations in clinical and animal studies.
Early Effects on Leptin, Glucose Tolerance, and FFA
The initial aims of the study were to determine if olanzapine
had early effects on leptin, oral glucose tolerance, and FFA in
otherwise healthy volunteers. Clinical studies have demonstrated
that leptin increases with chronic olanzapine treatment [35], [43],
[44], though this is expected as circulating leptin increases with
increased adipose tissue mass. In several animal models, though,
we have observed ,50% reductions in plasma leptin after acute
olanzapine administration [20], [25]. Thus, it is reasonable to
speculate that decreases in circulating leptin, a powerful regulator
of food intake and body weight, may underlie the eventual
increased adiposity and weight gain seen clinically. In our human
subjects, however, we detected a small but statistically significant
increase in leptin (,20%). This suggests that our efforts to
investigate the mechanism of leptin lowering in the rodents, while
of interest from a basic science perspective, might not be relevant
to humans, as increased serum leptin likely does not underlie the
increased hunger observed in patients taking olanzapine.
In addition to examining potential alterations in leptin, the
effects of atypical antipsychotics on insulin sensitivity in healthy
volunteers have been examined in a small number of studies using
hyperinsulinemic-euglycemic clamp methodology, the ‘gold-stan-
dard’ for measuring whole-body insulin sensitivity. As mentioned,
clamp studies in animals have demonstrated rapid induction of
insulin resistance by olanzapine and other atypical antipsychotics
[20], [21], [22], though studies following longer periods of drug
administration in healthy volunteers have yielded conflicting
results. Sowell and colleagues [29] failed to detect altered insulin
sensitivity following three weeks of olanzapine treatment. More
recently, though, others have shown that olanzapine decreases
insulin sensitivity in healthy males after either eight [16] or ten
days of administration [45]. The current study detected an
increase in the AUC glucose, consistent with decreased whole-
body insulin sensitivity, using the same dose of olanzapine (10 mg/
day) as each of these previous human clamp studies. Of note,
though, studies in animals have actually shown that olanzapine
and other antipsychotics decrease insulin sensitivity within the first
hour and possibly within minutes following drug administration.
Given the rapid onset of these effects, it would make sense to
conduct further studies along the same time course in healthy
human subjects to further validate the animal models.
Figure 4. Effect of olanzapine on plasma fasting free fatty
acids. Baseline blood samples were collected approximately 10–12 h
following the final dose of olanzapine or placebo tablets prior to
beginning an oral glucose tolerance test for hormone and metabolite
analyses. Plasma free fatty acid concentrations were measured for all
subjects under placebo- and olanzapine-treated conditions. Data are
expressed as a box plot for placebo and olanzapine-treated groups. An
asterisk indicates (P=0.016) a significant difference between the
medians of the placebo and olanzapine groups (n=15).
doi:10.1371/journal.pone.0022662.g004
Figure 5. Effect of olanzapine on plasma triglycerides. For each
subject baseline blood samples were drawn 10–12 h following the final
dose of placebo or olanzapine tablets prior to beginning an oral
glucose tolerance test for hormone and metabolite analyses. Plasma
triglyceride concentration was measured for all subjects under placebo-
and olanzapine-treated conditions. Data are expressed as a box plot for
placebo and olanzapine-treated groups. An asterisk indicates (P=0.017)
a significant difference between the medians of the placebo and
olanzapine groups (n=15).
doi:10.1371/journal.pone.0022662.g005
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chronic olanzapine is associated with decreased circulating free
fatty acid concentrations [16], [17]. Interestingly, lower FFA
concentrations were consistently observed in the olanzapine arm
of the current study, despite higher concentrations of FFA being
more closely associated with impaired glucose tolerance and
insulin resistance. The mechanism of this FFA lowering effect is
currently unknown, though in recent studies from our lab,
olanzapine increased fatty acid oxidation in peripheral tissues
and suppression of lipolysis in rats and mice [20]. In at least one
human study the rate of in vivo lipolysis was not affected by
olanzapine or haloperidol treatment in healthy subjects [16]. It is
tempting to speculate therefore that olanzapine-induced insulin
resistance cause an acute increase in fatty acid oxidation since
excessive fat oxidation is linked to tissue insulin resistance [46],
[47] while at the same time suppressing or preventing an increase
lipolysis normally associated with insulin resistant states [20].
Future mechanistic studies in animal models may be particularly
useful in determining the cause of this reproducible effect initially
described in clinical studies.
Effects of Olanzapine on Triglycerides and Cholesterol
Chronic antipsychotic therapy is associated with elevated
triglycerides and hypercholesterolemia, though most studies have
focused on measurements of insulin resistance and glucose into-
lerance. In rodents, acute olanzapine-induced insulin resistance is
associated with decreased triglycerides, consistent with drug-stimu-
lation of fatty fuel oxidation. Vidarsdottir and colleagues showed
that eight days of olanzapine, but not haloperidol, blunted the
insulin-mediated decreases in triglycerides during a hyperinsulin-
emic-euglycemic clamp [16]. Fasting triglycerides, though, were
unchanged in their study in contrast to the elevated triglycerides
that were observed in the current study.
Studying the cholesterol triglyceride effects of antipsychotics is
hindered in rodents, given that rodents do not have the same
susceptibilities to dyslipidemia and atherosclerosis as humans [48].
Regardless, it is clear that chronic antipsychotic treatment is
associated with increased total and LDL cholesterol as well as
decreases in HDL cholesterol clinically, reviewed in: [19], [40].
The current study examined three cholesterol species with stan-
dard lipid profiling that is routinely used in clinical laboratories.
We did not expect to observe alterations in cholesterol profiles in
the olanzapine group; however, the small but significant decline in
HDL raises the possibility that antipsychotics may have acute
adverse effects on cholesterol/lipid profiles as well. Better-
designed, more thorough clinical studies looking specifically at
plasma cholesterol species are needed to confirm rapid effects of
antipsychotics on cholesterol.
Generalizability and Limitations of the Trial
The purpose of the current study was to detect and validate
observations made from animal models in healthy human volun-
teers and thus provide ‘proof of concept’ that animal models
provide reliable information about the nature of the metabolic
effects of atypical antipsychotics. The strength of the trial is in its
design – prospective, double blind, randomized, and placebo-
controlled with crossover – to maximize sensitivity for detecting
acute metabolic changes. As within- and between-subject vari-
ability is inherent in clinical studies, we also opted to recruit a very
narrowly defined group of volunteers to maximize the sensitivity of
the trial. This design begs the question of how generalizable the
current findings are to other populations, especially those patients
receiving olanzapine therapeutically. This is obviously a limitation
of the current study, as it was not well designed for this purpose.
The sex-dependence of the olanzapine-induced hyperphagia and
weight gain in animals was also not examined in the current study,
which may or may not exist in humans [49]. With evidence of the
acute metabolic effects of olanzapine, these and other more
specific questions can be addressed in future studies.
The safety of the volunteers participating in the study was
particularly scrutinized by the investigators and the IRB prior to
study approval, since the inherent risks of side effects of receiving
olanzapine without any direct therapeutic benefit is not ethical.
The rapid time course of these effects in animals is what enabled us
to justify the short-term (3 day) exposure of otherwise healthy
volunteers with olanzapine. The most serious effects of olanzapine
(e.g. neuroleptic malignant syndrome, acute dystonic reaction)
were not observed in the current study, and were not expected
given that these are typically observed after chronic treatment (.6
months) with higher doses of olanzapine in much older popu-
lations. Individuals with a history of seizure and cardiac arrhy-
thmias were also excluded to decrease the chances of these adverse
events as well, even though risk of arrhythmia or seizure was
considered very low at this particular dosage and length of
exposure of olanzapine. None of the volunteers in the study
experienced any serious side effects during the olanzapine or
placebo arms of the trial. However, more than half of the
volunteers did subjectively report fatigue and tiredness, along with
dry mouth during the olanzapine arm of the study. With the
exception of one case of orthostatic hypotension that was
Figure 6. Effect of olanzapine on plasma cholesterol. Plasma
concentrations of (A) Total cholesterol, (B) High-density lipoprotein, and
(C) Low-density lipoprotein cholesterol were measured for all subjects
under placebo- and olanzapine-treated conditions. Data are expressed
as box plots for comparison of placebo and olanzapine-treated groups.
An asterisk indicates (P=0.018) a significant difference between the
medians of the placebo and olanzapine groups. NS=not significantly
different (n=15).
doi:10.1371/journal.pone.0022662.g006
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significant adverse effects of the short-term olanzapine treatment
in these otherwise healthy volunteers.
Conclusion
Overall this study demonstrates that olanzapine has rapid
metabolic effects in healthy human volunteers that are detectable
by at least the third day of drug administration. Contrary to
animal models, serum leptin appears to be increased, rather than
decreased and is likely not directly involved with increased caloric
intake in patients taking olanzapine. On the other hand, drug
effects on glucose tolerance and FFA lowering are similar to those
observed in animal models, and thus these models may be useful in
elucidating the physiologic basis of these effects in humans. The
acute onset of these metabolic effects may permit screening for
patient susceptibility to all or some of the adverse metabolic effects
of olanzapine prior to initiation of chronic therapy, though future
studies in patients are needed to correlate these acute metabolic
changes with chronic outcomes.
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